Literature DB >> 21741294

Cytokine expression and microglial activation in progressive supranuclear palsy.

Rafael Fernández-Botrán1, Zeshan Ahmed, Fabián A Crespo, Chandler Gatenbee, John Gonzalez, Dennis W Dickson, Irene Litvan.   

Abstract

Although little is known about the etiology of progressive supranuclear palsy (PSP), genetic and epigenetic factors, oxidative injury and inflammation are thought to contribute to its development and/or progression. Evidence for activated glia involvement in PSP has raised the possibility that neuroinflammation may contribute to its pathogenesis. To investigate the correlation between neuroinflammation and PSP, a comparative study was conducted on the patterns of cytokine expression in different regions of the brains of PSP, Alzheimer's disease (AD) patients and normal controls. Our results show different patterns of cytokine expression in each disease, with the expression of IL-1β transcripts being significantly higher in the substantia nigra of PSP than in AD and controls, while AD brains had significantly higher IL-1β expression in the parietal cortex compared to PSP and controls. In addition, expression of TGFβ was significantly higher in the cortical areas (particularly frontal and parietal lobes) of AD compared to PSP and controls. These results show a disease-specific topographical relationship among the expression of certain cytokines (IL-1β and TGFβ), microglial activation and neurodegenerative changes, suggesting that these cytokines may contribute to the pathologic process. If so, the use of cytokine-inhibitors and/or other anti-inflammatory agents may be able to slow disease progression in PSP.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21741294      PMCID: PMC3196843          DOI: 10.1016/j.parkreldis.2011.06.007

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  30 in total

1.  TGF-beta receptors-I and -II immunoexpression in Alzheimer's disease: a comparison with aging and progressive supranuclear palsy.

Authors:  C F Lippa; K C Flanders; E S Kim; S Croul
Journal:  Neurobiol Aging       Date:  1998 Nov-Dec       Impact factor: 4.673

2.  NSAID exposure and risk of Alzheimer disease: is timing everything?

Authors:  David A Bennett; Rachel A Whitmer
Journal:  Neurology       Date:  2009-04-22       Impact factor: 9.910

3.  Validation of the neuropathologic criteria of the third consortium for dementia with Lewy bodies for prospectively diagnosed cases.

Authors:  Hiroshige Fujishiro; Tanis J Ferman; Bradley F Boeve; Glenn E Smith; Neill R Graff-Radford; Ryan J Uitti; Zbigniew K Wszolek; David S Knopman; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2008-07       Impact factor: 3.685

4.  Cerebrovascular transforming growth factor-beta contributes to inflammation in the Alzheimer's disease brain.

Authors:  Paula Grammas; Roma Ovase
Journal:  Am J Pathol       Date:  2002-05       Impact factor: 4.307

5.  Microglial activation parallels system degeneration in progressive supranuclear palsy and corticobasal degeneration.

Authors:  K Ishizawa; D W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2001-06       Impact factor: 3.685

6.  Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease.

Authors:  G Boka; P Anglade; D Wallach; F Javoy-Agid; Y Agid; E C Hirsch
Journal:  Neurosci Lett       Date:  1994-05-19       Impact factor: 3.046

7.  Postmortem delay has minimal effect on brain RNA integrity.

Authors:  John F Ervin; Erin L Heinzen; Kenneth D Cronin; David Goldstein; Mari H Szymanski; James R Burke; Kathleen A Welsh-Bohmer; Christine M Hulette
Journal:  J Neuropathol Exp Neurol       Date:  2007-12       Impact factor: 3.685

8.  Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor-beta and interleukin-10.

Authors:  C Bogdan; J Paik; Y Vodovotz; C Nathan
Journal:  J Biol Chem       Date:  1992-11-15       Impact factor: 5.157

9.  Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology.

Authors:  Terrence Town; Yasmina Laouar; Christopher Pittenger; Takashi Mori; Christine A Szekely; Jun Tan; Ronald S Duman; Richard A Flavell
Journal:  Nat Med       Date:  2008-06-01       Impact factor: 53.440

Review 10.  Update on progressive supranuclear palsy.

Authors:  Irene Litvan
Journal:  Curr Neurol Neurosci Rep       Date:  2004-07       Impact factor: 5.081

View more
  31 in total

1.  microRNA profiling: increased expression of miR-147a and miR-518e in progressive supranuclear palsy (PSP).

Authors:  Roman Tatura; Malte Buchholz; Dennis W Dickson; John van Swieten; Catriona McLean; Günter Höglinger; Ulrich Müller
Journal:  Neurogenetics       Date:  2016-04-06       Impact factor: 2.660

2.  Progressive Supranuclear Palsy and Corticobasal Degeneration.

Authors:  David G Coughlin; Dennis W Dickson; Keith A Josephs; Irene Litvan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Nanoformulated Mutant SurR9-C84A: a Possible Key for Alzheimer's and its Associated Inflammation.

Authors:  Bhasker Sriramoju; Rupinder K Kanwar; Jagat R Kanwar
Journal:  Pharm Res       Date:  2015-03-14       Impact factor: 4.200

Review 4.  The emerging role of LRRK2 in tauopathies.

Authors:  Susanne Herbst; Patrick A Lewis; Huw R Morris
Journal:  Clin Sci (Lond)       Date:  2022-07-15       Impact factor: 6.876

5.  Progressive Supranuclear Palsy and Statin Use.

Authors:  Ece Bayram; Connie Marras; David G Standaert; Benzi M Kluger; Yvette M Bordelon; David R Shprecher; Irene Litvan
Journal:  Mov Disord       Date:  2020-03-27       Impact factor: 10.338

6.  Identification of Conserved Proteomic Networks in Neurodegenerative Dementia.

Authors:  Vivek Swarup; Timothy S Chang; Duc M Duong; Eric B Dammer; Jingting Dai; James J Lah; Erik C B Johnson; Nicholas T Seyfried; Allan I Levey; Daniel H Geschwind
Journal:  Cell Rep       Date:  2020-06-23       Impact factor: 9.423

Review 7.  Genetic and Transcriptomic Profiles of Inflammation in Neurodegenerative Diseases: Alzheimer, Parkinson, Creutzfeldt-Jakob and Tauopathies.

Authors:  Irene López González; Paula Garcia-Esparcia; Franc Llorens; Isidre Ferrer
Journal:  Int J Mol Sci       Date:  2016-02-04       Impact factor: 5.923

8.  Age-dependent neuroinflammation and cognitive decline in a novel Ala152Thr-Tau transgenic mouse model of PSP and AD.

Authors:  Astrid Sydow; Katja Hochgräfe; Stefanie Könen; Daniela Cadinu; Dorthe Matenia; Olga Petrova; Maria Joseph; Frank Johannes Dennissen; Eva-Maria Mandelkow
Journal:  Acta Neuropathol Commun       Date:  2016-02-25       Impact factor: 7.801

9.  Neuroinflammation and Tau Colocalize in vivo in Progressive Supranuclear Palsy.

Authors:  John T O'Brien; James B Rowe; Maura Malpetti; Luca Passamonti; Timothy Rittman; P Simon Jones; Patricia Vázquez Rodríguez; W Richard Bevan-Jones; Young T Hong; Tim D Fryer; Franklin I Aigbirhio
Journal:  Ann Neurol       Date:  2020-10-10       Impact factor: 11.274

Review 10.  Microglial dynamics and role in the healthy and diseased brain: a paradigm of functional plasticity.

Authors:  Diego Gomez-Nicola; V Hugh Perry
Journal:  Neuroscientist       Date:  2014-04-10       Impact factor: 7.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.